Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children With Juvenile Myelomonocytic Leukemia (JMML)

Trial Profile

A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children With Juvenile Myelomonocytic Leukemia (JMML)

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2018

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Melphalan (Primary) ; Busulfan; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
  • Indications Graft-versus-host disease; Juvenile myelomonocytic leukaemia
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 07 May 2018 Status changed from active, no longer recruiting to completed.
    • 28 Nov 2016 Status changed from suspended to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top